ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1409

Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study

Guillermo Guaracha Basañez1, Irazu Contreras-Yáñez2, Vivian Estrada-González2, Lexli Pacheco-Santiago2, Salvador Valverde-Hernández2 and Virginia Pascual Ramos3, 1Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico

Meeting: ACR Convergence 2022

Keywords: Health Care, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients and physicians can naturally adopt hybrid healthcare models (HC), that combine face-to-face consultations (FFC) with telemedicine. The study’s objective was to compare the impact of two healthcare interventions, HC and FFC, on the patient-reported outcomes (PROs) of RA patients, during the current COVID-19 pandemic.

Methods: Consecutive patients reincorporated to an outpatient clinic previously lockdown, were invited to a non-inferiority, crossover, and randomized study (October 2020-May 2022). Patients were randomized to six months of FFC or HC (intervention period-1) and then the converse modality (intervention period-2). Intervention period-1 was followed by two months “washout period”. The six months of FFC consisted of three to four consecutive standardized medical evaluations. The six months of HC consisted of three to four consecutive standardized medical evaluations, starting with a video conference consultation, and alternating with FFC, the period considered at least two video conference consultations. The primary outcome was disease activity/severity behavior (RAPID3). Additional PROs were disability (HAQ-DI), quality-of-life (WHOQOL-BREF), adherence to medical care, satisfaction with medical care, and treatment recommendations. Sample size calculation established 55 patients/healthcare intervention. To summarize PROs’ behavior during the study, Areas Under the Curve (AUC) were calculated.

Results: There were 138 patients invited to participate, 130 agreed and 121 completed their study participation. Sixty-one and 60 patients respectively, received FFC and HC over the intervention period-1. Patients were primarily middle-aged females (90.1%), with 12 (IQR 9-16) years of education, long-standing disease, receiving DMARDs (96.7%), and corticosteroids (61.2%). Overall, they had low disease activity (median RAPID3: 2.7), while the quality of life was compromised. Table 1 summarizes the baseline characteristics of the participants and their comparison based on healthcare modality received during intervention period-1. Table 2 summarizes the results from comparing period-1 and period-2 of primary and secondary outcomes between patients assigned to either healthcare modality. Differences in RAPID3 behavior were below the non-inferiority margin, the adjusted intervention effect was 0.7, 95% CI (-0.19 to 1.62), and p=0.151.Table 3 summarizes the RAPID3 behavior over the two treatment periods, based on the order in which patients received the health care intervention. Within individual differences in RAPID3 behavior were below the non-inferiority margin and considered the order in which patients received the intervention. Finally, in the HC group, there were 313 consultations, among whom 133 (42.5%) were video conference consultations. The FFC ended more frequently with increased and reduced treatment recommendations, while video conference consultations with an unchanged treatment recommendation (p=0.014).

Conclusion: HC was non-inferior to in-person consultations in achieving PROs during the COVID-19 pandemic in RA patients. HC model impacts treatment decisions by favoring a more “contemplative” approach to patients’ perceived outcomes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. Guaracha Basañez, None; I. Contreras-Yáñez, None; V. Estrada-González, None; L. Pacheco-Santiago, None; S. Valverde-Hernández, None; V. Pascual Ramos, None.

To cite this abstract in AMA style:

Guaracha Basañez G, Contreras-Yáñez I, Estrada-González V, Pacheco-Santiago L, Valverde-Hernández S, Pascual Ramos V. Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-a-hybrid-medical-care-model-in-the-rheumatoid-arthritis-patient-reported-outcomes-a-non-inferiority-crossover-randomized-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-a-hybrid-medical-care-model-in-the-rheumatoid-arthritis-patient-reported-outcomes-a-non-inferiority-crossover-randomized-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology